Form 4: Carlyle Group Sells Additional Shares of QuidelOrtho Corp (QDEL)

Carlyle Group continues to reduce its stake in QuidelOrtho Corp through a series of sales executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Carlyle Group, a major shareholder of QuidelOrtho Corp (QDEL), has sold a portion of its holdings.
• The sales occurred on July 12, 2024, and July 15, 2024.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on May 12, 2024.
• On July 12, 2024, Carlyle sold 4,722 shares at a weighted average price of $31.7063, with prices ranging from $31.36 to $31.99, and 52,531 shares at a weighted average price of $32.4089, with prices ranging from $32.02 to $32.70.
• On July 15, 2024, Carlyle sold 90,507 shares at a weighted average price of $31.6896, with prices ranging from $31.3251 to $31.996, and 2,680 shares at a weighted average price of $32.1535, with prices ranging from $32.00 to $32.2993.
• Following these transactions, Carlyle's indirect beneficial ownership stands at 10,894,562 shares.
• The shares are held of record by Carlyle Partners VI Cayman Holdings, L.P.
• Several entities within the Carlyle Group structure may be deemed to share beneficial ownership but disclaim it.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports share sales under a pre-existing plan. It doesn't inherently indicate positive or negative prospects for the company.

Negatives

• Carlyle Group is reducing its stake in QuidelOrtho, which could be interpreted negatively by the market.

Risks

• Continued sales by Carlyle Group could put downward pressure on QuidelOrtho's stock price.
• The market may react negatively to the ongoing reduction in Carlyle's position.

Industry Context

Share sales by major holders are common and can be part of portfolio management strategies. The impact on QuidelOrtho's stock will depend on market perception and overall company performance.

Comparison to Industry Standards

• It is common for large shareholders, such as private equity firms like Carlyle, to periodically reduce their holdings in portfolio companies.
• These sales are often conducted under pre-arranged trading plans (Rule 10b5-1) to avoid accusations of insider trading.
• Comparable transactions can be seen with other healthcare companies where private equity firms have taken significant stakes and then gradually reduced them over time.

Stakeholder Impact

• Shareholders may react to the news of Carlyle's share sales.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal unless the sales significantly affect the company's financial stability.

Key Dates